Pharmacogenomics of Human Drug Transporters
Clinical Impacts
1. Edition May 2013
440 Pages, Hardcover
Wiley & Sons Ltd
Short Description
Highlighting the internationally hot topic of pharmacogenomics and its influence on drug therapy, Pharmacogenomics of Human Drug Transporters reviews individual drug transporters, including specific transporter families and clinical implications. This book serves as a comprehensive guide to drug transporters that influence the absorption, distribution, and elimination of drugs in the body, and the reasons why individuals differ. The authors include sufficient detail to enable non-specialists to understand the principles and techniques and provides a practical, hands-on resource for researchers in pharmaceutical industry, academic research, and government agencies.
Highlighting the internationally hot topic of pharmacogenomics and its influence on drug therapy, Pharmacogenomics of Human Drug Transporters reviews individual drug transporters, including specific transporter families and clinical implications. This book serves as a comprehensive guide to drug transporters that influence the absorption, distribution, and elimination of drugs in the body, and the reasons why individuals differ. The authors include sufficient detail to enable non-specialists to understand the principles and techniques and provides a practical, hands-on resource for researchers in pharmaceutical industry, academic research, and government agencies.
CONTRIBUTORS ix
CHAPTER 1 INTRODUCTION TO PHARMACOGENOMICS OF DRUG TRANSPORTERS 1
Marianne K. DeGorter and Richard B. Kim
CHAPTER 2 ADME PHARMACOGENOMICS IN DRUG DEVELOPMENT 13
Liangfu Chen and Joseph W. Polli
CHAPTER 3 REGULATORY PERSPECTIVE ON PHARMACOGENOMICS OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS 39
Lei Zhang, Gilbert J. Burckart, Lawrence J. Lesko and Shiew-Mei Huang
CHAPTER 4 THE PHARMACOGENOMICS OF MEMBRANE TRANSPORTERS PROJECT 73
Sook Wah Yee, Deanna L. Kroetz and Kathleen M. Giacomini
CHAPTER 5 EMERGING NEW TECHNOLOGY OF SNP TYPING 109
Toshihisa Ishikawa and Yoshihide Hayashizaki
CHAPTER 6 OATP1A2, OAT1, AND OAT3 125
Rommel G. Tirona
CHAPTER 7 OATP1B1, OATP1B3, AND OATP2B1 141
J¨org K¨onig and Martin F. Fromm
CHAPTER 8 OCT (SLC22A) AND OCTN FAMILY 171
Sophie L. Stocker, Arian Emami Riedmaier, Matthias Schwab and Kathleen M. Giacomini
CHAPTER 9 MATE (SLC47) FAMILY 209
Atsushi Yonezawa and Ken-ichi Inui
CHAPTER 10 PEPT (SLC15A) FAMILY 223
Tomoko Sugiura, Saki Umeda, Akira Tsuji and Yukio Kato
CHAPTER 11 NUCLEOSIDE TRANSPORTERS (SLC28 AND SLC29) FAMILY 243
M´?riam Molina-Arcas and Marc¸al Pastor-Anglada
CHAPTER 12 P-GLYCOPROTEIN (MDR1/ABCB1) 271
Ingolf Cascorbi
CHAPTER 13 BSEP (ABCB11) 295
Bruno Stieger and Gerd A. Kullak-Ublick
CHAPTER 14 BCRP (ABCG2) 311
Agnes Basseville, Susan E. Bates, William D. Figg and Alex Sparreboom
CHAPTER 15 MRP2 (ABCC2) AND MRP3 (ABCC3) 345
Anne T. Nies
CHAPTER 16 MRP4 (ABCC4) 365
Satish B. Cheepala, Mugdha Sukthankar and John D. Schuetz
CHAPTER 17 MRP8 (ABCC11) 387
Yu Toyoda and Toshihisa Ishikawa
CHAPTER 18 FUTURE PERSPECTIVES 401
Toshihisa Ishikawa and Joseph Ware
INDEX 417
RICHARD B. KIM, MD, FRCPC, is Professor and Chair of the Division of Clinical Pharmacology and Associate Chair for Research in the Department of Medicine at the University of Western Ontario. He is a Fellow of the American Association of Pharmaceutical Scientists and an elected member of the American Society for Clinical Investigation.
JÖRG KÖNIG, PhD, is Professor and Head of the Molecular Biology Laboratories in the Department of Clinical Pharmacology at the Friedrich-Alexander Universität Erlangen-Nürnberg.
